JP2013501033A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013501033A5 JP2013501033A5 JP2012523344A JP2012523344A JP2013501033A5 JP 2013501033 A5 JP2013501033 A5 JP 2013501033A5 JP 2012523344 A JP2012523344 A JP 2012523344A JP 2012523344 A JP2012523344 A JP 2012523344A JP 2013501033 A5 JP2013501033 A5 JP 2013501033A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical preparation
- preparation according
- lipocalin
- lipocalin mutein
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000825 pharmaceutical preparation Substances 0.000 claims 25
- 102000019298 Lipocalin Human genes 0.000 claims 20
- 108050006654 Lipocalin Proteins 0.000 claims 20
- 239000002202 Polyethylene glycol Substances 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 229920001477 hydrophilic polymer Polymers 0.000 claims 6
- 229920000747 poly(lactic acid) Polymers 0.000 claims 6
- 229920001223 polyethylene glycol Polymers 0.000 claims 6
- 229920000642 polymer Polymers 0.000 claims 6
- 101000946124 Homo sapiens Lipocalin-1 Proteins 0.000 claims 5
- 229920000954 Polyglycolide Polymers 0.000 claims 5
- 229920002988 biodegradable polymer Polymers 0.000 claims 5
- 239000004621 biodegradable polymer Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 108010088751 Albumins Proteins 0.000 claims 4
- 102000009027 Albumins Human genes 0.000 claims 4
- 238000013270 controlled release Methods 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 102000009333 Apolipoprotein D Human genes 0.000 claims 3
- 108010025614 Apolipoproteins D Proteins 0.000 claims 3
- 102000014914 Carrier Proteins Human genes 0.000 claims 3
- 102000013382 Gelatinases Human genes 0.000 claims 3
- 108010026132 Gelatinases Proteins 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 229920001273 Polyhydroxy acid Polymers 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 108091008324 binding proteins Proteins 0.000 claims 3
- 229920001577 copolymer Polymers 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 150000004676 glycans Chemical class 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 210000000440 neutrophil Anatomy 0.000 claims 3
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 3
- -1 polyacetyl Polymers 0.000 claims 3
- 239000004633 polyglycolic acid Substances 0.000 claims 3
- 239000004626 polylactic acid Substances 0.000 claims 3
- 229920001282 polysaccharide Polymers 0.000 claims 3
- 239000005017 polysaccharide Substances 0.000 claims 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 2
- 101000757556 Homo sapiens Apolipoprotein D Proteins 0.000 claims 2
- 108010057281 Lipocalin 1 Proteins 0.000 claims 2
- 102000003752 Lipocalin 1 Human genes 0.000 claims 2
- 229920002732 Polyanhydride Polymers 0.000 claims 2
- 229920001710 Polyorthoester Polymers 0.000 claims 2
- 102000044159 Ubiquitin Human genes 0.000 claims 2
- 108090000848 Ubiquitin Proteins 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 210000004907 gland Anatomy 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- 102000056778 human APOD Human genes 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 150000002632 lipids Chemical class 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 claims 2
- 108090000195 villin Proteins 0.000 claims 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 1
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Polymers OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims 1
- 102000008300 Mutant Proteins Human genes 0.000 claims 1
- 108010021466 Mutant Proteins Proteins 0.000 claims 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 241000255969 Pieris brassicae Species 0.000 claims 1
- 101000766245 Pieris brassicae Bilin-binding protein Proteins 0.000 claims 1
- 239000004743 Polypropylene Substances 0.000 claims 1
- 101100049197 Rattus norvegicus Vegp1 gene Proteins 0.000 claims 1
- 101100049198 Rattus norvegicus Vegp2 gene Proteins 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- FBPFZTCFMRRESA-NQAPHZHOSA-N Sorbitol Polymers OCC(O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-NQAPHZHOSA-N 0.000 claims 1
- 101710153009 Uterocalin Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 239000013566 allergen Substances 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 239000008346 aqueous phase Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 claims 1
- 239000012964 benzotriazole Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 150000002303 glucose derivatives Polymers 0.000 claims 1
- 150000002304 glucoses Polymers 0.000 claims 1
- 125000002791 glucosyl group Polymers C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 150000002314 glycerols Polymers 0.000 claims 1
- 229940050526 hydroxyethylstarch Drugs 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- JUZGXATTXYZBGK-HBVDJMOISA-N lancerin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(O)C2=C1OC1=CC=C(O)C=C1C2=O JUZGXATTXYZBGK-HBVDJMOISA-N 0.000 claims 1
- FTAGCSGVWJQDNN-UHFFFAOYSA-N lancerin Natural products COc1ccc2Oc3c(C4OC(CO)C(O)C(O)C4O)c(O)cc(O)c3C(=O)c2c1 FTAGCSGVWJQDNN-UHFFFAOYSA-N 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 229920002521 macromolecule Polymers 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 239000012074 organic phase Substances 0.000 claims 1
- 229920001308 poly(aminoacid) Polymers 0.000 claims 1
- 239000002745 poly(ortho ester) Substances 0.000 claims 1
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 claims 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 claims 1
- 229920001281 polyalkylene Polymers 0.000 claims 1
- 229920001515 polyalkylene glycol Polymers 0.000 claims 1
- 229920001610 polycaprolactone Polymers 0.000 claims 1
- 239000004632 polycaprolactone Substances 0.000 claims 1
- 229920000515 polycarbonate Polymers 0.000 claims 1
- 239000004417 polycarbonate Substances 0.000 claims 1
- 229920002721 polycyanoacrylate Polymers 0.000 claims 1
- 239000000622 polydioxanone Substances 0.000 claims 1
- 229920006149 polyester-amide block copolymer Polymers 0.000 claims 1
- 229920001155 polypropylene Polymers 0.000 claims 1
- 229920001451 polypropylene glycol Polymers 0.000 claims 1
- 229920002635 polyurethane Polymers 0.000 claims 1
- 239000004814 polyurethane Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 108020001580 protein domains Proteins 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 208000004644 retinal vein occlusion Diseases 0.000 claims 1
- 102000029752 retinol binding Human genes 0.000 claims 1
- 108091000053 retinol binding Proteins 0.000 claims 1
- 229960002317 succinimide Drugs 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 125000003396 thiol group Chemical class [H]S* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23136509P | 2009-08-05 | 2009-08-05 | |
| US61/231,365 | 2009-08-05 | ||
| PCT/EP2010/061436 WO2011015634A2 (en) | 2009-08-05 | 2010-08-05 | Controlled release formulations of lipocalin muteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012176112A Division JP5774557B2 (ja) | 2009-08-05 | 2012-08-08 | リポカリン突然変異タンパク質の制御放出製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013501033A JP2013501033A (ja) | 2013-01-10 |
| JP2013501033A5 true JP2013501033A5 (enExample) | 2013-09-12 |
Family
ID=43531164
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012523344A Pending JP2013501033A (ja) | 2009-08-05 | 2010-08-05 | リポカリン突然変異タンパク質の制御放出製剤 |
| JP2012176112A Expired - Fee Related JP5774557B2 (ja) | 2009-08-05 | 2012-08-08 | リポカリン突然変異タンパク質の制御放出製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012176112A Expired - Fee Related JP5774557B2 (ja) | 2009-08-05 | 2012-08-08 | リポカリン突然変異タンパク質の制御放出製剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20120201873A1 (enExample) |
| EP (2) | EP2550958B1 (enExample) |
| JP (2) | JP2013501033A (enExample) |
| KR (1) | KR20120099371A (enExample) |
| CN (2) | CN102612362A (enExample) |
| AU (2) | AU2010280688A1 (enExample) |
| BR (1) | BR112012002709A2 (enExample) |
| CA (1) | CA2770149A1 (enExample) |
| IN (1) | IN2012DN00407A (enExample) |
| RU (1) | RU2012107812A (enExample) |
| WO (1) | WO2011015634A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011106702A2 (en) | 2010-02-25 | 2011-09-01 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
| WO2012109363A2 (en) | 2011-02-08 | 2012-08-16 | The Johns Hopkins University | Mucus penetrating gene carriers |
| US9701732B2 (en) | 2011-02-28 | 2017-07-11 | Korea University Research And Business Foundation | Fusion protein comprising albumin and retinol-binding protein |
| EP2682406B1 (en) * | 2011-02-28 | 2018-05-09 | Korea University Research and Business Foundation | Fusion protein comprising albumin and a retinol-binding protein |
| US10064915B2 (en) | 2011-02-28 | 2018-09-04 | Korea University Research And Business Foundation | Fusion protein comprising albumin and retinol-binding protein |
| BR112013027222B1 (pt) * | 2011-06-14 | 2022-07-12 | Ipsen Pharma S.A.S. | Composição de liberação sustentada que contém peptídeos como ingrediente ativo |
| WO2013068590A1 (en) * | 2011-11-11 | 2013-05-16 | Pieris Ag | Lipocalin muteins as vegf antagonists for use in treating diseases caused or promoted by increased vascularization |
| EP2802341B1 (en) | 2012-01-09 | 2019-03-06 | Pieris Pharmaceuticals GmbH | Methods for preventing, treating or diagnosing disorders |
| ES2604837T3 (es) | 2012-02-02 | 2017-03-09 | Esbatech - A Novartis Company Llc | Formulación de liberación sostenida que contiene anticuerpos para administración ocular |
| US8962577B2 (en) | 2012-03-16 | 2015-02-24 | The Johns Hopkins University | Controlled release formulations for the delivery of HIF-1 inhibitors |
| EP2825207B1 (en) | 2012-03-16 | 2020-08-19 | The Johns Hopkins University | Non-linear multiblock copolymer-drug conjugates for the delivery of active agents |
| US9533068B2 (en) | 2012-05-04 | 2017-01-03 | The Johns Hopkins University | Drug loaded microfiber sutures for ophthalmic application |
| US10568975B2 (en) | 2013-02-05 | 2020-02-25 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
| CN103360609B (zh) * | 2013-07-16 | 2015-08-19 | 天津大学 | 一种双亲性的蛋白质-高分子键合体及其制备方法 |
| CN103394094B (zh) * | 2013-07-16 | 2015-05-13 | 天津大学 | 基于牛血清白蛋白-聚己内酯的高分子脂质体及其制备方法 |
| AU2015205530B8 (en) * | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| US10046058B2 (en) | 2014-12-02 | 2018-08-14 | Rezolute, Inc. | Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates |
| AU2016211696B2 (en) | 2015-01-27 | 2018-05-10 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
| CN107636014B (zh) | 2015-05-04 | 2021-12-07 | 皮里斯制药有限公司 | 抗癌融合多肽 |
| WO2017141106A1 (en) * | 2016-02-16 | 2017-08-24 | Strongbridge Biopharma plc | Veldoreotide with poor solubitliy in physiological conditions for use in the treatment of acromegaly, acromegaly cancer, sst-r5 expressing tumors, type 2 diabetes, hyperglycemia, and hormone-related tumors |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5349052A (en) | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
| IE912365A1 (en) | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US5417982A (en) * | 1994-02-17 | 1995-05-23 | Modi; Pankaj | Controlled release of drugs or hormones in biodegradable polymer microspheres |
| US5650234A (en) | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
| US5869079A (en) * | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| WO1997004747A1 (en) | 1995-07-27 | 1997-02-13 | Dunn James M | Drug delivery systems for macromolecular drugs |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| PL192364B1 (pl) | 1998-06-08 | 2006-10-31 | Hoffmann La Roche | Zastosowanie koniugatu PEG-IFN-α 2A w połączeniu z rybawiryną |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| DE19926068C1 (de) | 1999-06-08 | 2001-01-11 | Arne Skerra | Muteine des Bilin-Bindungsproteins |
| MXPA02003540A (es) | 1999-10-08 | 2003-09-12 | Nektar Therapeutics Al Corp | Derivados de poli(etilenglicol) heterobifuncionales y los metodos para su preparacion. |
| CN101584867A (zh) * | 2000-10-31 | 2009-11-25 | 瑟莫迪克斯药品公司 | 提高生物活性分子传递的方法和组合物 |
| CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
| EP1430136A1 (en) | 2001-09-27 | 2004-06-23 | Pieris ProteoLab AG | Muteins of apolipoprotein d |
| WO2003029462A1 (en) | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
| CN101514223B (zh) | 2003-04-11 | 2017-03-01 | 安特里阿比奥有限公司 | 位点特异性蛋白质偶联物的制备方法 |
| EP2462896A1 (en) * | 2003-07-15 | 2012-06-13 | PR Pharmaceuticals Inc. | Method for the preparation of controlled release formulations |
| BRPI0412211A (pt) * | 2003-07-23 | 2006-08-22 | Pr Pharmaceuticals Inc | composições de liberação controlada |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7691970B2 (en) | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| EP2899277A1 (en) | 2004-11-26 | 2015-07-29 | Pieris AG | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| US20070212703A1 (en) | 2005-09-27 | 2007-09-13 | Stemmer Willem P | Proteinaceous pharmaceuticals and uses thereof |
| EP1996613B1 (en) * | 2006-03-20 | 2014-04-30 | Technische Universität München | Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4 |
| AU2007280398B2 (en) * | 2006-08-01 | 2012-05-10 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
| US8178483B2 (en) * | 2007-03-30 | 2012-05-15 | Colgate-Palmolive Company | Polymeric encapsulates having a quaternary ammonium salt and methods for producing the same |
| US8263327B2 (en) * | 2007-04-26 | 2012-09-11 | Basf Se | Enzymatic method for the production of microcapsules |
| ES2443537T3 (es) * | 2007-07-26 | 2014-02-19 | Aqtis Ip Bv | Micropartículas que comprenden PCL y usos de las mismas |
| NZ621174A (en) * | 2008-01-15 | 2015-09-25 | Abbvie Deutschland | Powdered protein compositions and methods of making same |
| US20090274623A1 (en) * | 2008-01-30 | 2009-11-05 | General Electric Company | In vivo imaging agents for met receptor tyrosine kinase |
| CA2713557C (en) * | 2008-01-30 | 2016-06-07 | Pieris Ag | Muteins of tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the same |
-
2010
- 2010-08-05 CN CN2010800348503A patent/CN102612362A/zh active Pending
- 2010-08-05 IN IN407DEN2012 patent/IN2012DN00407A/en unknown
- 2010-08-05 EP EP12177932.6A patent/EP2550958B1/en not_active Not-in-force
- 2010-08-05 RU RU2012107812/15A patent/RU2012107812A/ru not_active Application Discontinuation
- 2010-08-05 BR BR112012002709-3A patent/BR112012002709A2/pt not_active IP Right Cessation
- 2010-08-05 KR KR1020127005597A patent/KR20120099371A/ko not_active Ceased
- 2010-08-05 AU AU2010280688A patent/AU2010280688A1/en not_active Abandoned
- 2010-08-05 JP JP2012523344A patent/JP2013501033A/ja active Pending
- 2010-08-05 CN CN201610084958.2A patent/CN106139123A/zh active Pending
- 2010-08-05 US US13/388,788 patent/US20120201873A1/en not_active Abandoned
- 2010-08-05 EP EP10747840A patent/EP2461800A2/en not_active Withdrawn
- 2010-08-05 WO PCT/EP2010/061436 patent/WO2011015634A2/en not_active Ceased
- 2010-08-05 CA CA2770149A patent/CA2770149A1/en not_active Abandoned
-
2012
- 2012-08-08 JP JP2012176112A patent/JP5774557B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-07 AU AU2016204715A patent/AU2016204715A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013501033A5 (enExample) | ||
| RU2012107812A (ru) | Препараты мутеинов липокалинов с контролируемым высвобождением | |
| Pang et al. | Polymer-drug conjugates: recent progress on administration routes | |
| Škalko-Basnet | Biologics: the role of delivery systems in improved therapy | |
| Akash et al. | IL-1Ra and its delivery strategies: inserting the association in perspective | |
| CN103827177B (zh) | 用于生物活性化合物的受控释放的生物可降解的、半结晶的、相分离的、热塑性多嵌段共聚物 | |
| EP2585098B1 (en) | Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules for use in treating obesity and obesity-related disorders | |
| Wu et al. | Optimization of protein and peptide drugs based on the mechanisms of kidney clearance | |
| JP2014526441A5 (enExample) | ||
| AU2017205268A1 (en) | CNP prodrugs with large carrier moieties | |
| IL293979A (en) | Controlled-release cnp agonists with increased nep stability | |
| JP2013519697A5 (enExample) | ||
| JP2014524480A (ja) | 徐放のための活性剤の製剤 | |
| TW201012489A (en) | Encapsulation of biologically active agents | |
| Yi et al. | Brain delivery of proteins via their fatty acid and block copolymer modifications | |
| JP4966434B2 (ja) | 結合抗体の存在下における組換え血液凝固因子のｐｅｇ化 | |
| JP2015227385A (ja) | 血液凝固タンパク質複合体 | |
| WO2020093789A1 (zh) | 用于改善活性蛋白或多肽性能的人工重组蛋白及其应用 | |
| Yoon et al. | In vivo residence duration of human growth hormone loaded in nanogels comprising cinnamoyl alginate, cinnamoyl Pluronic F127 and cinnamoyl poly (ethylene glycol) | |
| CN102038938A (zh) | 利用IFN-β治疗慢性炎性脱髓鞘性多神经病 | |
| Bansal et al. | Nanopharmacy: Exploratory Methods for Polymeric Materials | |
| CN119390758B (zh) | 一种靶向dec-205口服疫苗及其构建方法与应用 | |
| CN114075265A (zh) | 一种多肽酪氨酸酪氨酸类似物以及包含其的缓释制剂 | |
| WO2024233456A1 (en) | Variants of adrenomedullin (am) and adrenomedullin 2/intermedin (am2/imd) and methods of use | |
| WO2014024189A1 (en) | Pegylated high affinity leptins with increased biological activity |